TG Therapeutics Announces Follow-Up Data From The Chemo-Free Triple Combination Of TG-1101, TGR-1202, And Ibrutinib At The 53rd Annual Meeting Of The ASCO Post author:Sam Post published:June 4, 2017 Post category:BioPharma Life Sciences Jobs … Source: BioSpace You Might Also Like Peregrine Reports Financial Results For The Third Quarter Of Fiscal Year 2017 And Recent Developments March 13, 2017 Why This Seattle Biotech Could be an M&A Target January 18, 2018 Proteostasis Therapeutics Snags Breakthrough Designation March 12, 2018
Peregrine Reports Financial Results For The Third Quarter Of Fiscal Year 2017 And Recent Developments March 13, 2017